Iratumumab
Iratumumab
Iratumumab (pronounced as i-ra-tu-mu-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a type of immunotherapy that targets specific proteins on cancer cells to help the immune system recognize and destroy them.
Etymology
The name "Iratumumab" is derived from the International Nonproprietary Names (INN), where "ira" refers to the target, "tu" denotes the product class, "mu" indicates the source (human), and "mab" is the suffix for monoclonal antibodies.
Usage
Iratumumab is used in the treatment of various types of cancers, including melanoma, lung cancer, and colorectal cancer. It works by binding to the specific proteins on the surface of cancer cells, thereby helping the immune system to recognize and destroy these cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Melanoma: A form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin.
- Lung cancer: A type of cancer that begins in the lungs and most often occurs in people who smoke.
- Colorectal cancer: A cancer that starts in the colon or the rectum.
External links
- Medical encyclopedia article on Iratumumab
- Wikipedia's article - Iratumumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski